U.S. Markets closed

MolMed S.p.A. (MLM.MI)

Milan - Milan Delayed Price. Currency in EUR
Add to watchlist
0.4178-0.0008 (-0.1911%)
At close: 5:35PM CEST

MolMed S.p.A.

Via Olgettina, 58
Milan, MI 20132
39 02 21 27 71

Full Time Employees

Key Executives

Dr. Claudio Bordignon M.D.Founder, Chairman, Pres and Chairman of Scientific Advisory Board674kN/AN/A
Dr. Riccardo PalmisanoChief Exec. Officer and Director601kN/AN/A
Mr. Gian Paolo Rizzardi M.D.Gen. Mang. of R&D & Operations and Director of R&D262kN/AN/A
Ms. Marina Del Bue B.Sc., M.B.A.Bus. Devel. & IR Director and Gen. Mang. Bus. & Admin.30kN/AN/A
Mr. Andrea QuaglinoChief Financial Officer and Director of Admin., Fin. & ControlN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of anticancer therapies. The company’s products include Zalmoxis (TK), a cell based therapy product, which is in Phase III clinical trial in acute leukemia that is used for the treatment of hematological malignancies. Its products also comprise NGR-hTNF, a therapeutic agent for solid tumors, which is in Phase II trials in seven types of solid tumors, such as monotherapy in colorectal cancer, hepatocellular carcinoma, and mesothelioma; and in combination with standard chemotherapeutic agents in small-cell lung cancer, non-small cell lung cancer, ovarian cancer, and soft-tissue sarcoma, as well as in Phase III trials in mesothelioma patients. In addition, the company’s preclinical development products include CAR-CD44v6, an immuno-gene therapy project for the treatment of various hematological malignancies and epithelial tumors. Further, it conducts cell and gene therapy projects in collaboration with third parties, such as the cGMP production of clinical-grade viral vectors; and manufacturing of patient-specific genetically engineered cells. The company was founded in 1996 and is headquartered in Milan, Italy.

Corporate Governance

MolMed S.p.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.